Cubist (CBST) and Ariad (ARIA) Epidemic Upward Path on Trading

The price of Cubist Pharmaceuticals Inc. (CBST) stock jumped $5.26 (or +8.03%) to $70.76 after the company reported positive top-line results from pivotal Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections.

CBST 's ceftolozane/tazobactam, an antibiotic candidate being developed to treat certain Gram-negative infections, met its primary endpoint of statistical non-inferiority compared to levofloxacin (10% non-inferiority margin)

CBST is concluding a pivotal Phase 3 trial of ceftolozane/tazobactam in patients with complicated intra-abdominal infections, which is comparing the safety and efficacy of ceftolozane/tazobactam in combination with metronidazole relative to the comparator meropenem. CBST expects to announce top-line data from this trial in late December

CBST is a global biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment.

More about Cubist Pharmaceuticals Inc. (CBST) at www.cubist.com .

**

Shares of Ariad Pharmaceuticals Inc. (ARIA) soared $1.35 (or +35.74%) to $5.13 on Monday's market activity.

Last week, ARIA reported adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency on the continued availability of Iclusig(R) (ponatinib) in the EU for use in patients with leukaemias in its authorized indications with extra safety precautions to safeguard patients against an increased risk of occlusive vascular events.

ARIA 's Iclusig was approved in July in Europe and last year in the U.S. for two rare blood cancers. According to the average of nine analysts’ estimates compiled by Bloomberg, the treatment is expected to generate revenue of $52 million next year.

ARIA is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.

More about Ariad Pharmaceuticals Inc. (ARIA) at www.ariad.com

**

Today, the Internet has become a world-wide marketplace. In fact, many small scale businesses are using eCommerce to build exposure and compete with much larger businesses.

Looking to deliver value for its stockholders in both the near and long term, Crown Equity Holdings Inc. (CRWE) is refocusing its strategic plan to improve the potential future growth for the company, targeting the multi-billion dollar online b2b market, with its ts iB2B Global project.

As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. CRWE launches, invests and manages select businesses, projects and real estate endeavors.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Read Full Disclaimer at www.drstockpick.com/disclaimer